Relapsed disease following conventional therapy remains one of the central problems in the treatment of leukemia. Leukemia initiating cells (LIC), possess stem cell properties such as self-renewal and pluripotency enabling them to mediate disease initiation and maintenance. Targeting the LIC compartment is therefore at the core of novel therapeutic approaches to leukemia. We have demonstrated that the Promyelocytic Leukemia gene (PML) is critical to HSC and CML LIC maintenance. Notably, pharmacologic ablation of PML using arsenic trioxide (ATO) combined with cytotoxic therapy resulted in the exhaustion of LICs and eradication of disease in a BCR-ABL CML murine model. Our preclinical findings led to a phase I trial at our institution combining TKI and ATO in CML patients with evidence of persistent disease, as well as a multi-center, randomized trial in China comparing TKI and TKI plus a novel oral arsenic in CML. Encouraging interim results of our own trial prompted the addition of a new site as well as collaboration with our colleagues in China. Our ongoing studies of PML's role in HSC and LIC maintenance has uncovered evidence of a novel non-cell- autonomous role for PML in HSCs and in CML and AML LICs through its expression in mesenchymal stem cells suggesting that PML targeting strategies could be dually effective against the leukemic niche and LIC proper. Furthermore, we discovered a cell-autonomous, metabolic dimension to PML-orchestrated HSC maintenance via the nutrient sensor, peroxisome proliferator activating receptor ? (PPAR ?) and fatty acid oxidation (FAO) which promote HSC asymmetric division. In AML, we have intriguing evidence that abrogating PPAR signaling with a novel PPAR? inhibitor markedly inhibits colony initiating capacity. In addition, our preliminary data indicates that the combination of ATO and PPAR inhibition results in synergistic cytotoxicity in part through increased ROS production. Given the ROS-low status of the AML LIC compartment, we postulate that this combination could efficiently target the LIC compartment in specific subtypes of AML, such as IDH mutant leukemia, which is known to have limited reducing capacity. To translate the potential of targeting PML pathways, we propose to conduct the following Specific Aims: (1) to define the subtypes of AML that rely on Pml expression in MSCs for LIC maintenance and dissect the MSC-derived factors that mediate LIC maintenance in CML and AML (2) to study the role of the PML/PPAR/FAO pathway in AML LICs; (3) to assess the effectiveness of combinatorial treatments targeting PML pathways, against AML LICs in preclinical murine models, including IDH2-mutant models, with evaluation of PML targeting strategies in combination with IDH2-mutant deinduction and (4) to develop a clinical trial of PPAR? inhibition alone or in combination with ATO for the treatment of relapsed, refractory AML. The studies proposed will significantly impact the treatment of CML and AML patients by targeting the reservoir of leukemic cells that mediates disease persistence and relapse.

Public Health Relevance

Emerging evidence points to a pivotal role for PML in the maintenance of hematopoietic stem cells and leukemia initiating cells. Leukemia initiating cells are resistant to the current standard of care for CML and AML and can thus act as a reservoir of disease that results in disease relapse; effectively targeting this subpopulation of leukemic cells with stem cell-like properties, is a fundamental problem in leukemia treatment protocols. This proposal aims to i. finely characterize the mechanisms by which PML supports the maintenance of CML and AML leukemia initiating cells and ii. investigate rational combinations of targeted therapies directed at PML mechanisms of sustaining leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA142874-08
Application #
9402584
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Merritt, William D
Project Start
2010-01-01
Project End
2020-12-31
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
8
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Song, Su Jung; Pandolfi, Pier Paolo (2014) MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. Curr Opin Hematol 21:276-82
Stroopinsky, Dina; Rosenblatt, Jacalyn; Ito, Keisuke et al. (2013) MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res 73:5569-79
Dos Santos, Guilherme Augusto; Kats, Lev; Pandolfi, Pier Paolo (2013) Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 210:2793-802
Carracedo, Arkaitz; Ito, Keisuke; Pandolfi, Pier Paolo (2011) The nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin Cell Biol 23:360-6
Giorgi, Carlotta; Ito, Keisuke; Lin, Hui-Kuan et al. (2010) PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 330:1247-51